Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-Hodgkin's lymphoma
John P. Leonard, Brian K. Link, Christos Emmanouilides, Stephanie A. Gregory, Daniel Weisdorf, Jeffrey Andrey, John Hainsworth, Joseph A. Sparano, Donald E. Tsai, Sandra Horning, Arthur M. Krieg, George J. Weiner
Dive into the research topics of 'Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-Hodgkin's lymphoma'. Together they form a unique fingerprint.